“[Cost-Effectiveness Analysis of Maribavir in Patients With Post-Transplant Cytomegalovirus Infection or Disease That Are Refractory or Resistant to Conventional Therapy]”. Farmeconomia. Health Economics and Therapeutic Pathways 24, no. 1 (December 7, 2023). Accessed February 15, 2026. https://journals.seedstm.com/index.php/FE/article/view/1548.